{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:08:52Z","timestamp":1779354532427,"version":"3.51.4"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"DOI":"10.1007\/s10354-026-01156-5","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:21:01Z","timestamp":1779351661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive review on myasthenia gravis: patho-physiology, diagnosis, management strategies","Umfassende \u00dcbersicht zur Myasthenia gravis: Pathophysiologie, Diagnose, Behandlungsstrategien"],"prefix":"10.1007","author":[{"given":"Ifeoma Nneozor","family":"Ozor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anes Abdulmajid","family":"Hwidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerrin Jolly","family":"Kuriakose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Hajj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Iwuagwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidhi Kashyap","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa Hassan Mohammed Elsayed","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long Yin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"2","key":"1156_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology. Neurologic Clinics. 2018;36(2):253\u201360. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.002.","journal-title":"Neurologic Clinics"},{"issue":"7","key":"1156_CR2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-19-363","volume":"11","author":"Y Li","year":"2023","unstructured":"Li Y, Peng Y, Yang H. Serological diagnosis of myasthenia gravis and its clinical significance. Ann Transl Med. 2023;11(7)290. https:\/\/doi.org\/10.21037\/atm-19-363.","journal-title":"Ann Transl Med"},{"key":"1156_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, et\u00a0al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J\u00a0Neurol. 2016;263:1473\u201394. https:\/\/doi.org\/10.1007\/s00415-016-8045-z.","journal-title":"J Neurol"},{"issue":"1","key":"1156_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, Jaretzki A, Barohn RJ, et\u00a0al. Myasthenia gravis. Neurology. 2000;55(1):16\u201323. https:\/\/doi.org\/10.1212\/WNL.55.1.16.","journal-title":"Neurology"},{"issue":"9","key":"1156_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106757","volume":"9","author":"T Akaishi","year":"2014","unstructured":"Akaishi T, Yamaguchi T, Suzuki Y, et\u00a0al. Insights into the Classification of Myasthenia Gravis. PLoS One. 2014;9(9)e106757. https:\/\/doi.org\/10.1371\/journal.pone.0106757.","journal-title":"PLoS One"},{"issue":"6","key":"1156_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current Treatment of Myasthenia Gravis. J\u00a0Clin Med. 2022;11(6)1597. https:\/\/doi.org\/10.3390\/jcm11061597.","journal-title":"J Clin Med"},{"key":"1156_CR7","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8206.1","volume":"5","author":"WD Phillips","year":"2016","unstructured":"Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016;5:F1000 Faculty Rev-1513. https:\/\/doi.org\/10.12688\/f1000research.8206.1.","journal-title":"F1000Res"},{"issue":"2","key":"1156_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","volume":"135","author":"N Kim","year":"2008","unstructured":"Kim N, Stiegler AL, Cameron TO, et\u00a0al. Lrp4 is a\u00a0Receptor for Agrin and Forms a\u00a0Complex with MuSK. Cell. 2008;135(2):334\u201342. https:\/\/doi.org\/10.1016\/j.cell.2008.10.002.","journal-title":"Cell"},{"issue":"4","key":"1156_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4103\/0972-2327.44560","volume":"11","author":"PS Bindu","year":"2008","unstructured":"Bindu PS, Nirmala M, Patil SA, Taly AB. Myasthenia gravis and acetylcholine receptor antibodies: A clinico immunological correlative study on South Indian patients. Ann Indian Acad Neurol. 2008;11(4):242\u20134. https:\/\/doi.org\/10.4103\/0972-2327.44560.","journal-title":"Ann Indian Acad Neurol"},{"key":"1156_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00660","volume":"11","author":"C Rodolico","year":"2020","unstructured":"Rodolico C, Bonanno C, Toscano A, Vita G. MuSK-Associated Myasthenia Gravis: Clinical Features and Management. Front Neurol. 2020;11:660. https:\/\/doi.org\/10.3389\/fneur.2020.00660.","journal-title":"Front Neurol"},{"issue":"12","key":"1156_CR11","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1172\/JCI66039","volume":"123","author":"C Shen","year":"2013","unstructured":"Shen C, Lu Y, Zhang B, et\u00a0al. Antibodies against low-density lipoprotein receptor\u2013related protein 4 induce myasthenia gravis. J\u00a0Clin Invest. 2013;123(12):5190\u2013202. https:\/\/doi.org\/10.1172\/JCI66039.","journal-title":"J Clin Invest"},{"issue":"9","key":"1156_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13091286","volume":"13","author":"C Vinciguerra","year":"2023","unstructured":"Vinciguerra C, Bevilacqua L, Lupica A, et\u00a0al. Diagnosis and Management of Seronegative Myasthenia Gravis: Lights and Shadows. Brain Sci. 2023;13(9)1286. https:\/\/doi.org\/10.3390\/brainsci13091286.","journal-title":"Brain Sci"},{"issue":"1","key":"1156_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/1759-7714.13724","volume":"12","author":"A De Rosa","year":"2021","unstructured":"De Rosa A, Fornili M, Maestri Tassoni M, et\u00a0al. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. Thorac Cancer. 2021;12(1):106\u201313. https:\/\/doi.org\/10.1111\/1759-7714.13724.","journal-title":"Thorac Cancer"},{"issue":"2","key":"1156_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1212\/WNL.34.2.170","volume":"34","author":"A Sghirlanzoni","year":"1984","unstructured":"Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis. Neurology. 1984;34(2):170\u2013170. https:\/\/doi.org\/10.1212\/WNL.34.2.170.","journal-title":"Neurology"},{"key":"1156_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/EB.S389629","volume":"15","author":"R Behbehani","year":"2023","unstructured":"Behbehani R. Ocular Myasthenia Gravis: A Current Overview. Eye Brain. 2023;15:1\u201313. https:\/\/doi.org\/10.2147\/EB.S389629.","journal-title":"Eye Brain"},{"issue":"11","key":"1156_CR16","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S, et\u00a0al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020;94(11):e1171\u2013e80. https:\/\/doi.org\/10.1212\/WNL.0000000000008903.","journal-title":"Neurology"},{"issue":"7","key":"1156_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28893","volume":"10","author":"C Sun","year":"2024","unstructured":"Sun C, Ren Z, Miao X, et\u00a0al. Clinical characteristics of late-onset myasthenia gravis. Heliyon. 2024;10(7)e28893. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28893.","journal-title":"Heliyon"},{"key":"1156_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578241","volume":"385","author":"M Yasuda","year":"2023","unstructured":"Yasuda M, Uzawa A, Kuwabara S, et\u00a0al. Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan. Journal of Neuroimmunology. 2023;385:578241. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578241.","journal-title":"Journal of Neuroimmunology"},{"issue":"12","key":"1156_CR19","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","volume":"268","author":"N K\u00f6nig","year":"2021","unstructured":"K\u00f6nig N, Stetefeld HR, Dohmen C, et\u00a0al. MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation. J\u00a0Neurol. 2021;268(12):4824\u201333. https:\/\/doi.org\/10.1007\/s00415-021-10603-9.","journal-title":"J Neurol"},{"key":"1156_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123047","author":"R Ricciardi","year":"2024","unstructured":"Ricciardi R, Latini E, Guida M, et\u00a0al. Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: Results of a study on 202 patients. Journal of the Neurological Sciences. 2024; https:\/\/doi.org\/10.1016\/j.jns.2024.123047.","journal-title":"Journal of the Neurological Sciences"},{"issue":"15_supplement","key":"1156_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.P5.4-040","volume":"92","author":"S Pesala","year":"2019","unstructured":"Pesala S, Dimachkie MM, Rivner MH, et\u00a0al. Clinical and demographic features of LRP4 positive myasthenia gravis patients (P5.4-040). Neurology. 2019;92(15_supplement)P5.4-040. https:\/\/doi.org\/10.1212\/WNL.92.15_supplement.P5.4-040.","journal-title":"Neurology"},{"issue":"3","key":"1156_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/mus.26985","volume":"62","author":"MH Rivner","year":"2020","unstructured":"Rivner MH, Quarles BM, Pan JX, et\u00a0al. Clinical features of LRP4\/agrin-antibody\u2013positive myasthenia gravis: A multicenter study. Muscle Nerve. 2020;62(3):333\u201343. https:\/\/doi.org\/10.1002\/mus.26985.","journal-title":"Muscle Nerve"},{"key":"1156_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.873599","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Tao X, Wang Y, et\u00a0al. Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody. Front Neurol. 2022;13:873599. https:\/\/doi.org\/10.3389\/fneur.2022.873599.","journal-title":"Front Neurol"},{"issue":"9","key":"1156_CR24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","volume":"73","author":"E Cort\u00e9s-Vicente","year":"2016","unstructured":"Cort\u00e9s-Vicente E, Gallardo E, Mart\u00ednez M\u00c1, et\u00a0al. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurol. 2016;73(9):1099\u2013104. https:\/\/doi.org\/10.1001\/jamaneurol.2016.2032.","journal-title":"JAMA Neurol"},{"key":"1156_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1555075","author":"S Lehnerer","year":"2025","unstructured":"Lehnerer S, Stegherr R, Grittner U, et\u00a0al. The burden of disease in seronegative myasthenia gravis: a patient-centered perspective. Front Immunol. 2025; https:\/\/doi.org\/10.3389\/fimmu.2025.1555075.","journal-title":"Front Immunol"},{"issue":"12","key":"1156_CR26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50017","volume":"15","author":"AK Mishra","year":"2023","unstructured":"Mishra AK, Varma A. Myasthenia Gravis: A Systematic Review. Cureus. 2023;15(12)e50017. https:\/\/doi.org\/10.7759\/cureus.50017.","journal-title":"Cureus"},{"issue":"3","key":"1156_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.17712\/nsj.2019.3.20190011","volume":"24","author":"MH Alanazy","year":"2019","unstructured":"Alanazy MH. Clinical features and outcomes of patients with myasthenia gravis. Neurosciences (Riyadh). 2019;24(3):176\u201384. https:\/\/doi.org\/10.17712\/nsj.2019.3.20190011.","journal-title":"Neurosciences (Riyadh)"},{"key":"1156_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120084","volume":"432","author":"A Mirian","year":"2022","unstructured":"Mirian A, Nicolle MW, Edmond P, Budhram A. Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis. J\u00a0Neurol Sci. 2022;432:120084. https:\/\/doi.org\/10.1016\/j.jns.2021.120084.","journal-title":"J Neurol Sci"},{"issue":"3","key":"1156_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3233\/JND-230210","volume":"11","author":"L Diogenes","year":"2024","unstructured":"Diogenes L, Dellavance A, Baldo DC, et\u00a0al. Detection of Autoantibodies Against the Acetylcholine Receptor, Evaluation of Commercially Available Methodologies: Fixed Cell-Based Assay, Radioimmunoprecipitation Assay and Enzyme-Linked Immunosorbent Assay1. J\u00a0Neuromuscul Dis. 2024;11(3):613\u201323. https:\/\/doi.org\/10.3233\/JND-230210.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"1156_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3988\/jcn.2023.19.1.60","volume":"19","author":"HY Chung","year":"2023","unstructured":"Chung HY, Kim MJ, Kim SW, Oh J, Shin HY. Development and Application of a Cell-Based Assay for LRP4 Antibody Associated With Myasthenia Gravis. Journal of Clinical Neurology. 2023;19(1):60\u20136. https:\/\/doi.org\/10.3988\/jcn.2023.19.1.60.","journal-title":"Journal of Clinical Neurology"},{"key":"1156_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577850","volume":"367","author":"G Masi","year":"2022","unstructured":"Masi G, Li Y, Karatz T, et\u00a0al. The clinical need for clustered AChR cell-based assay testing of seronegative MG. J\u00a0Neuroimmunol. 2022;367:577850. https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577850.","journal-title":"J Neuroimmunol"},{"issue":"6","key":"1156_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/archneur.58.6.885","volume":"58","author":"AM Yamamoto","year":"2001","unstructured":"Yamamoto AM, Gajdos P, Eymard B, et\u00a0al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol. 2001;58(6):885\u201390. https:\/\/doi.org\/10.1001\/archneur.58.6.885.","journal-title":"Arch Neurol"},{"key":"1156_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1459423","author":"JS Tzartos","year":"2025","unstructured":"Tzartos JS, Vakrakou AG, Karagiorgou K, et\u00a0al. Efficiency of cell-based assays in detecting AChR antibodies in myasthenia gravis sera with low antibody concentrations as determined by radioimmunoprecipitation assay. Front Immunol. 2025; https:\/\/doi.org\/10.3389\/fimmu.2025.1459423.","journal-title":"Front Immunol"},{"key":"1156_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30154-5","volume":"13","author":"M Tomschik","year":"2023","unstructured":"Tomschik M, Renaud E, J\u00e4ger F, et\u00a0al. The diagnostic and prognostic utility of repetitive nerve stimulation in patients with myasthenia gravis. Sci Rep. 2023;13:2985. https:\/\/doi.org\/10.1038\/s41598-023-30154-5.","journal-title":"Sci Rep"},{"issue":"8","key":"1156_CR35","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.clinph.2019.04.005","volume":"130","author":"DB Sanders","year":"2019","unstructured":"Sanders DB, Arimura K, Cui L, et\u00a0al. Guidelines for single fiber EMG. Clinical Neurophysiology. 2019;130(8):1417\u201339. https:\/\/doi.org\/10.1016\/j.clinph.2019.04.005.","journal-title":"Clinical Neurophysiology"},{"key":"1156_CR36","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/474512","volume":"2011","author":"F Romi","year":"2011","unstructured":"Romi F. Thymoma in Myasthenia Gravis: From Diagnosis to Treatment. Autoimmune Dis. 2011;2011:474512. https:\/\/doi.org\/10.4061\/2011\/474512.","journal-title":"Autoimmune Dis"},{"issue":"2","key":"1156_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-2000-9938","volume":"48","author":"S Christiansen","year":"2000","unstructured":"Christiansen S, Marx A, Kiefer R, Scheld HH, Semik M. Small thymomas and myasthenia gravis: a poorly understood association. Thorac Cardiovasc Surg. 2000;48(2):109\u201311. https:\/\/doi.org\/10.1055\/s-2000-9938.","journal-title":"Thorac Cardiovasc Surg"},{"issue":"5","key":"1156_CR38","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/j.crad.2014.01.005","volume":"69","author":"AM Priola","year":"2014","unstructured":"Priola AM, Priola SM. Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor. Clin Radiol. 2014;69(5):e230\u201345. https:\/\/doi.org\/10.1016\/j.crad.2014.01.005.","journal-title":"Clin Radiol"},{"issue":"1","key":"1156_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.21883","volume":"43","author":"TM Burns","year":"2011","unstructured":"Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB, MG Composite and MG-OL15 Study Group. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve. 2011;43(1):14\u20138. https:\/\/doi.org\/10.1002\/mus.21883.","journal-title":"Muscle Nerve"},{"issue":"18","key":"1156_CR40","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns TM, Conaway M, Sanders DB. The MG Composite. Neurology. 2010;74(18):1434\u201340. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1b1e.","journal-title":"Neurology"},{"issue":"7","key":"1156_CR41","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139. https:\/\/doi.org\/10.1212\/wnl.52.7.1487.","journal-title":"Neurology"},{"key":"1156_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596382","author":"JLS Thomsen","year":"2020","unstructured":"Thomsen JLS, Andersen H. Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis. Front Neurol. 2020; https:\/\/doi.org\/10.3389\/fneur.2020.596382.","journal-title":"Front Neurol"},{"issue":"10","key":"1156_CR43","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","volume":"31","author":"L Maggi","year":"2011","unstructured":"Maggi L, Mantegazza R. Treatment of Myasthenia Gravis. Clin Drug Investig. 2011;31(10):691\u2013701. https:\/\/doi.org\/10.2165\/11593300-000000000-00000.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1156_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002828.pub2","volume":"2005","author":"C Schneider-Gold","year":"2005","unstructured":"Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;2005(2)CD002828. https:\/\/doi.org\/10.1002\/14651858.CD002828.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1156_CR45","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ana.410150615","volume":"15","author":"AS Witte","year":"1984","unstructured":"Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Ann Neurol. 1984;15(6):602\u20135. https:\/\/doi.org\/10.1002\/ana.410150615.","journal-title":"Ann Neurol"},{"key":"1156_CR46","doi-asserted-by":"publisher","unstructured":"Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007;(4):CD005224. https:\/\/doi.org\/10.1002\/14651858.CD005224.pub2","DOI":"10.1002\/14651858.CD005224.pub2"},{"issue":"1","key":"1156_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-025-04681-0","volume":"25","author":"MTH Godarzi","year":"2025","unstructured":"Godarzi MTH, Rashid M, Abrotan S, Fallah M, Seifi M, Nikbakhsh N. Pyridostigmine-induced complete atrioventricular block in a patient with Musk antibody-negative myasthenia gravis a case report. BMC Cardiovascular Disorders. 2025;25(1)225. https:\/\/doi.org\/10.1186\/s12872-025-04681-0.","journal-title":"BMC Cardiovascular Disorders"},{"key":"1156_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006986.pub3","author":"MM Mehndiratta","year":"2014","unstructured":"Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Library. 2014; https:\/\/doi.org\/10.1002\/14651858.CD006986.pub3.","journal-title":"Cochrane Library"},{"issue":"7","key":"1156_CR49","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.nmd.2013.03.013","volume":"23","author":"V Zouvelou","year":"2013","unstructured":"Zouvelou V, Zisimopoulou P, Rentzos M, et\u00a0al. Double seronegative myasthenia gravis with anti-LRP 4 antibodies. Neuromuscular Disorders. 2013;23(7):568\u201370. https:\/\/doi.org\/10.1016\/j.nmd.2013.03.013.","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"1156_CR50","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/wnl.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B, Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998;50(6):1778\u201383. https:\/\/doi.org\/10.1212\/wnl.50.6.1778.","journal-title":"Neurology"},{"issue":"6","key":"1156_CR51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ncpneuro0810","volume":"4","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Rev Neurol. 2008;4(6):317\u201327. https:\/\/doi.org\/10.1038\/ncpneuro0810.","journal-title":"Nat Rev Neurol"},{"key":"1156_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00868","author":"T Imai","year":"2020","unstructured":"Imai T, Suzuki S, Nagane Y, Uzawa A, Murai H, Utsugisawa K. Reappraisal of Oral Steroid Therapy for Myasthenia Gravis. Front Neurol. 2020; https:\/\/doi.org\/10.3389\/fneur.2020.00868.","journal-title":"Front Neurol"},{"issue":"1","key":"1156_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00063030-199809010-00004","volume":"9","author":"A Anstey","year":"1998","unstructured":"Anstey A, Lear JT. Azathioprine: clinical pharmacology and current indications in autoimmune disorders. BioDrugs. 1998;9(1):33\u201347. https:\/\/doi.org\/10.2165\/00063030-199809010-00004.","journal-title":"BioDrugs"},{"key":"1156_CR54","doi-asserted-by":"publisher","unstructured":"Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(4):CD001461. https:\/\/doi.org\/10.1002\/14651858.CD001461.","DOI":"10.1002\/14651858.CD001461"},{"issue":"6","key":"1156_CR55","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2147\/ndt.s3309","volume":"4","author":"C Heatwole","year":"2008","unstructured":"Heatwole C, Ciafaloni E. Mycophenolate mofetil for myasthenia gravis: a clear and present controversy. Neuropsychiatr Dis Treat. 2008;4(6):1203\u20139. https:\/\/doi.org\/10.2147\/ndt.s3309.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"1156_CR56","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R, et\u00a0al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400\u20136. https:\/\/doi.org\/10.1212\/01.wnl.0000312374.95186.cc.","journal-title":"Neurology"},{"key":"1156_CR57","unstructured":"Lessons from Two Trials of Mycophenolate Mofetil in Myasthenia Gravis - Sanders - 2008 - Annals of the New York Academy of Sciences - Wiley Online Library. Accessed June\u00a027, 2025. https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1405.031."},{"issue":"3","key":"1156_CR58","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1474-4422(24)00028-0","volume":"23","author":"P Narayanaswami","year":"2024","unstructured":"Narayanaswami P, Sanders DB, Thomas L, et\u00a0al. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study. The Lancet Neurology. 2024;23(3):267\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(24)00028-0.","journal-title":"The Lancet Neurology"},{"issue":"2","key":"1156_CR59","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","volume":"8","author":"JL Cruz","year":"2015","unstructured":"Cruz JL, Wolff ML, Vanderman AJ, Brown JN. The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord. 2015;8(2):92\u2013103. https:\/\/doi.org\/10.1177\/1756285615571873.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"1156_CR60","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.nmd.2021.02.010","volume":"31","author":"K Itani","year":"2021","unstructured":"Itani K, Nakamura M, Wate R, et\u00a0al. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis. Neuromuscular Disorders. 2021;31(6):512\u20138. https:\/\/doi.org\/10.1016\/j.nmd.2021.02.010.","journal-title":"Neuromuscular Disorders"},{"issue":"9","key":"1156_CR61","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","volume":"82","author":"H Yoshikawa","year":"2011","unstructured":"Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. Journal of Neurology, Neurosurgery Psychiatry. 2011;82(9):970\u20137. https:\/\/doi.org\/10.1136\/jnnp-2011-300148.","journal-title":"Journal of Neurology, Neurosurgery Psychiatry"},{"issue":"7","key":"1156_CR62","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.transproceed.2008.07.094","volume":"40","author":"H Takeuchi","year":"2008","unstructured":"Takeuchi H, Matsuno N, Hirano T, et\u00a0al. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level. Transplant Proc. 2008;40(7):2240\u20132. https:\/\/doi.org\/10.1016\/j.transproceed.2008.07.094.","journal-title":"Transplant Proc"},{"issue":"1","key":"1156_CR63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","volume":"87","author":"M Pasnoor","year":"2016","unstructured":"Pasnoor M, He J, Herbelin L, et\u00a0al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016;87(1):57\u201364. https:\/\/doi.org\/10.1212\/WNL.0000000000002795.","journal-title":"Neurology"},{"issue":"3","key":"1156_CR64","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00415-019-09622-4","volume":"267","author":"E Gomez-Figueroa","year":"2020","unstructured":"Gomez-Figueroa E, Garcia-Trejo S, Bazan-Rodriguez L, et\u00a0al. Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. J\u00a0Neurol. 2020;267(3):674\u20138. https:\/\/doi.org\/10.1007\/s00415-019-09622-4.","journal-title":"J Neurol"},{"issue":"3","key":"1156_CR65","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et\u00a0al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000011124.","journal-title":"Neurology"},{"key":"1156_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212757","volume":"14","author":"AG Vakrakou","year":"2023","unstructured":"Vakrakou AG, Karachaliou E, Chroni E, et\u00a0al. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease. Front Immunol. 2023;14:1212757. https:\/\/doi.org\/10.3389\/fimmu.2023.1212757.","journal-title":"Front Immunol"},{"issue":"1","key":"1156_CR67","doi-asserted-by":"publisher","first-page":"7219","DOI":"10.1038\/s41598-025-90937-w","volume":"15","author":"S Chayanopparat","year":"2025","unstructured":"Chayanopparat S, Banyatcharoen P, Jitprapaikulsan J, Uawithya E, Apiraksattayakul N, Viarasilpa V. Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis. Sci Rep. 2025;15(1):7219\u20137219. https:\/\/doi.org\/10.1038\/s41598-025-90937-w.","journal-title":"Sci Rep"},{"issue":"4","key":"1156_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-014-0283-8","volume":"16","author":"K El-Salem","year":"2014","unstructured":"El-Salem K, Yassin A, Al-Hayk K, Yahya S, Al-Shorafat D, Dahbour SS. Treatment of MuSK-Associated Myasthenia Gravis. Curr Treat Options Neurol. 2014;16(4)283. https:\/\/doi.org\/10.1007\/s11940-014-0283-8.","journal-title":"Curr Treat Options Neurol"},{"key":"1156_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596621","author":"H Frykman","year":"2020","unstructured":"Frykman H, Kumar P, Oger J. Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies. Front Neurol. 2020; https:\/\/doi.org\/10.3389\/fneur.2020.596621.","journal-title":"Front Neurol"},{"issue":"2","key":"1156_CR70","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/sjmms.sjmms_80_22","volume":"10","author":"D Aljaafari","year":"2022","unstructured":"Aljaafari D, Ishaque N. Thymectomy in Myasthenia Gravis: A Narrative Review. Saudi J Med Med Sci. 2022;10(2):97\u2013104. https:\/\/doi.org\/10.4103\/sjmms.sjmms_80_22.","journal-title":"Saudi J Med Med Sci"},{"issue":"1","key":"1156_CR71","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5152\/eurasianjmed.2017.17009","volume":"49","author":"Y Aydin","year":"2017","unstructured":"Aydin Y, Ulas AB, Mutlu V, Colak A, Eroglu A. Thymectomy in Myasthenia Gravis. Eurasian J Med. 2017;49(1):48\u201352. https:\/\/doi.org\/10.5152\/eurasianjmed.2017.17009.","journal-title":"Eurasian J Med"},{"issue":"6","key":"1156_CR72","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, et\u00a0al. Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine. 2016;375(6):511\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1602489.","journal-title":"New England Journal of Medicine"},{"key":"1156_CR73","unstructured":"The role of thymectomy in myasthenia gravis: A\u00a0programmatic approach to thymectomy and perioperative management of myasthenia gravis - ScienceDirect. Accessed June\u00a027, 2025. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1015958421000014"},{"issue":"4","key":"1156_CR74","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/mus.26404","volume":"59","author":"KM Clifford","year":"2019","unstructured":"Clifford KM, Hobson-Webb LD, Benatar M, et\u00a0al. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle Nerve. 2019;59(4):404\u201310. https:\/\/doi.org\/10.1002\/mus.26404.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1156_CR75","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et\u00a0al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419\u201325. https:\/\/doi.org\/10.1212\/WNL.0000000000002790.","journal-title":"Neurology"},{"key":"1156_CR76","unstructured":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis | Neurology. Accessed June\u00a027, 2025. https:\/\/www.neurology.org\/doi\/10.1212\/01.WNL.0000150587.71497.B6."},{"key":"1156_CR77","unstructured":"The evidence is stacked against thymectomy in MuSK myasthenia gravis - Kushlaf - 2019 - Muscle & Nerve - Wiley Online Library. Accessed June\u00a027, 2025. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.26439"},{"issue":"3","key":"1156_CR78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1600-0404.2006.00733.x","volume":"115","author":"HK Yuan","year":"2007","unstructured":"Yuan HK, Huang BS, Kung SY, Kao KP. The effectiveness of thymectomy on seronegative generalized myasthenia gravis: comparing with seropositive cases. Acta Neurol Scand. 2007;115(3):181\u20134. https:\/\/doi.org\/10.1111\/j.1600-0404.2006.00733.x.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1156_CR79","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.autrev.2018.07.011","volume":"18","author":"I Koneczny","year":"2019","unstructured":"Koneczny I, Rennspiess D, Marcuse F, et\u00a0al. Characterization of the thymus in Lrp4 myasthenia gravis: Four cases. Autoimmunity Reviews. 2019;18(1):50\u20135. https:\/\/doi.org\/10.1016\/j.autrev.2018.07.011.","journal-title":"Autoimmunity Reviews"},{"key":"1156_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.662856","volume":"12","author":"TS Ipe","year":"2021","unstructured":"Ipe TS, Davis AR, Raval JS. Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence. Front Neurol. 2021;12:662856. https:\/\/doi.org\/10.3389\/fneur.2021.662856.","journal-title":"Front Neurol"},{"issue":"12","key":"1156_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002277.pub4","volume":"2012","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;2012(12)CD002277. https:\/\/doi.org\/10.1002\/14651858.CD002277.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"1156_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1275533","volume":"14","author":"A Vesperinas-Castro","year":"2023","unstructured":"Vesperinas-Castro A, Cort\u00e9s-Vicente E. Rituximab treatment in myasthenia gravis. Front Neurol. 2023;14:1275533. https:\/\/doi.org\/10.3389\/fneur.2023.1275533.","journal-title":"Front Neurol"},{"issue":"12","key":"1156_CR83","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, et\u00a0al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1156_CR84","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, et\u00a0al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evidence. 2022;1(5)EVIDoa2100066. https:\/\/doi.org\/10.1056\/EVIDoa2100066.","journal-title":"NEJM Evidence"},{"issue":"2","key":"1156_CR85","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(25)00001-8","volume":"24","author":"C Schneider-Gold","year":"2025","unstructured":"Schneider-Gold C, Gold R. Therapies for myasthenia gravis: FcRn inhibition and beyond. The Lancet Neurology. 2025;24(2):88\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(25)00001-8.","journal-title":"The Lancet Neurology"},{"issue":"5","key":"1156_CR86","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et\u00a0al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. The Lancet Neurology. 2023;22(5):383\u201394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7.","journal-title":"The Lancet Neurology"},{"issue":"8","key":"1156_CR87","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.4103\/1673-5374.363824","volume":"18","author":"LN Zhu","year":"2023","unstructured":"Zhu LN, Hou HM, Wang S, et\u00a0al. FcRn inhibitors: a novel option for the treatment of myasthenia gravis. Neural Regen Res. 2023;18(8):1637\u201344. https:\/\/doi.org\/10.4103\/1673-5374.363824.","journal-title":"Neural Regen Res"},{"issue":"1","key":"1156_CR88","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic Crisis. Neurohospitalist. 2011;1(1):16\u201322. https:\/\/doi.org\/10.1177\/1941875210382918.","journal-title":"Neurohospitalist"},{"issue":"6","key":"1156_CR89","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4103\/ijp.IJP_452_17","volume":"50","author":"R Bansal","year":"2018","unstructured":"Bansal R, Goyal MK, Modi M. Management of myasthenia gravis during pregnancy. Indian J Pharmacol. 2018;50(6):302\u20138. https:\/\/doi.org\/10.4103\/ijp.IJP_452_17.","journal-title":"Indian J Pharmacol"},{"issue":"11","key":"1156_CR90","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bjae.2021.07.001","volume":"21","author":"P Daum","year":"2021","unstructured":"Daum P, Smelt J, Ibrahim IR. Perioperative management of myasthenia gravis. BJA Education. 2021;21(11):414\u20139. https:\/\/doi.org\/10.1016\/j.bjae.2021.07.001.","journal-title":"BJA Education"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-026-01156-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10354-026-01156-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-026-01156-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:21:05Z","timestamp":1779351665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10354-026-01156-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":90,"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1007\/s10354-026-01156-5","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors confirm that there are no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}